Spotlight Series on Hepatitis C


Which Hepatitis C Treatment to Start in 2017

August 17, 2017



Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi): Pan-Genotypic and Salvage Therapy

The newest player in the DAA market is sofosbuvir/velpatasvir/voxilaprevir, a triple-drug regimen that was approved to treat all patients with HCV genotypes 1-6 and without cirrhosis or with only minor cirrhosis. In addition, the drug is the first to be approved to treat patients who have previously failed treatment with an NS5A inhibitor.

Sofosbuvir/velpatasvir/voxilaprevir is essentially a new-and-improved version of the two-drug combo sofosbuvir/velpatasvir. Both are made by Gilead, which also makes earlier blockbusters sofosbuvir and sofosbuvir/ledipasvir (Harvoni). Gilead has made waves for its high price tags, famously pricing sofosbuvir at $1,000 per pill. At $74,760 for a 12-week course of treatment, sofosbuvir/velpatasvir/voxilaprevir isn't significantly more discounted than prior regimens from Gilead. Ultimately, a prescription for sofosbuvir/velpatasvir/voxilaprevir may come down to the preferred status of Gilead's drug in the eyes of each patient's insurance plan.

Sofosbuvir/velpatasvir/voxilaprevir is likely to be a good option (both medically and financially) for tough-to-treat patients who have previously failed treatment with an NS5A inhibitor.

Image credit: Gilead Sciences, Inc.

Related Stories

The Need for a Codified Hepatitis C Care Continuum
Could the HIV Treatment-as-Prevention Model Work for Hepatitis C?

This article was provided by


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.